Sugi Predict

Sugi Predict / Compounds / SCHEMBL449212

SCHEMBL449212

SCHEMBL449212

CS(=O)(=O)Nc1ccccc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 3/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ NFE2L2 Q16236 1/20 0.52
▸ KMT2A Q03164 2/20 0.49
▸ EP300 Q09472 1/20 0.47
▸ KAT2B Q92831 1/20 0.47
▸ KAT8 Q9H7Z6 1/20 0.47
▸ PLA2G7 Q13093 1/20 0.47
▸ GAA P10253 3/20 0.46
▸ GLO1 Q04760 2/20 0.44
▸ NR3C1 P04150 2/20 0.44
▸ PGR P06401 2/20 0.44
▸ NR3C2 P08235 2/20 0.44
▸ AR P10275 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29396266 1.00 KEAP1 (0.55) KEAP1L3MBTL1NFE2L2KMT2AEP300
Hydrochloric Acid SCHEMBL8118011 0.98 KEAP1 (0.53) KEAP1L3MBTL1NFE2L2KMT2AEP300
SCHEMBL29904739 0.84 KEAP1 (0.65) KEAP1L3MBTL1NFE2L2KMT2AEP300
SCHEMBL2068498 0.84 KEAP1 (0.65) KEAP1L3MBTL1NFE2L2KMT2AEP300
SCHEMBL3962709 0.82 KEAP1 (0.67) KEAP1L3MBTL1NFE2L2KMT2APLA2G7
SCHEMBL21870755 0.80 KEAP1 (0.50) KEAP1L3MBTL1NFE2L2KMT2AEP300
SCHEMBL4090066 0.80 KEAP1 (0.50) KEAP1L3MBTL1NFE2L2KMT2APLA2G7
SCHEMBL19439099 0.80 CA2 (0.52) KMT2AGAAALOX15KDM4EMAPT
SCHEMBL11722241 0.79 PSIP1 (0.61) KMT2AGAANR3C1NR3C2HTT
SCHEMBL10695718 0.78 HDAC3 (0.46) KMT2AGAAALOX15KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7173060-B2 Oxime derivatives and their use as pharmaceutically active agents HOFFMANN-LA ROCHE INC. 2007-02-06 — — US claimed
EP-1613622-A1 OXIME DERIVATIVES AND THEIR USE AS PHARMACEUTICALLY ACTIVE AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-01-11 — — EP claimed
US-20040214880-A1 Oxime derivatives and their use as pharmaceutically active agents HOFFMANN-LA ROCHE INC. 2004-10-28 — — US claimed
WO-2004087693-A1 OXIME DERIVATIVES AND THEIR USE AS PHARMACEUTICALLY ACTIVE AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-14 — — WO claimed
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 — — EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 — — US disclosed
EP-4592286-A1 MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR Artivila Biopharma (CN) 2025-07-30 — — EP disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 — — US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 — — US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 — — WO disclosed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
CN-113896744-B Selective EGFR inhibitor 成都先导药物开发股份有限公司 2024-04-16 — — CN disclosed
EP-0093591-B1 SELECTIVE SULFONATION PROCESS ELI LILLY AND COMPANY (US) 1986-01-15 — — EP disclosed
EP-0151369-A2 Asymmetrical 1:2 chrome complexes containing an azo compound and an azomethine compound CIBA-GEIGY AG (CH) 1985-08-14 — — EP disclosed
EP-0093591-A1 Selective sulfonation process ELI LILLY AND COMPANY (US) 1983-11-09 — — EP disclosed
EP-0018939-B1 1:2 METAL COMPLEX DYESTUFFS OF AZOMETHINES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR DYEING AND PRINTING BY USING THESE DYESTUFFS CIBA-GEIGY AG (CH) 1983-10-05 — — EP disclosed
US-4315854-A Chromium and cobalt complex amino hydroxy azomethine dyes CIBA-GEIGY CORPORATION (US) 1982-02-16 — — US disclosed
EP-0018939-A1 1:2 Metal complex dyestuffs of azomethines, process for their preparation and process for dyeing and printing by using these dyestuffs CIBA-GEIGY AG (CH) 1980-11-12 — — EP disclosed
US-4018814-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-04-19 — — US disclosed
US-4013676-A NEMATOCIDES BAYER AKTIENGESELLSCHAFT (DT) 1977-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417396-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 KEAP1 3317/4885L3MBTL1 1360/4885NFE2L2 2685/4885
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 KEAP1 2533/4885L3MBTL1 1941/4885NFE2L2 1193/4885
US-12358904-B2 Inhibitors of TYK2 TYK2, LCK, JAK2 KEAP1 3317/4885L3MBTL1 1360/4885NFE2L2 2685/4885
US-20040214880-A1 Oxime derivatives and their use as pharmaceutically active agents HDAC1, HDAC2, HDAC5 KEAP1 599/4885L3MBTL1 4436/4885NFE2L2 118/4885
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 KEAP1 1916/4885L3MBTL1 2287/4885NFE2L2 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.